Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Expects Favorable Labeling For Oncologic Sutent

This article was originally published in The Pink Sheet Daily

Executive Summary

Labeling for sunitinib “might surprise us all,” CEO McKinnell tells investors.

You may also be interested in...



Pfizer's Sutent Receives Dual Approvals For Kidney Cancer & Stomach Cancer

Pfizer's Sutent received accelerated approval for first-line treatment of advanced renal cell carcinoma and full approval for treatment of refractory gastrointestinal stromal tumors.

Pfizer's Sutent Receives Dual Approvals For Kidney Cancer & Stomach Cancer

Pfizer's Sutent received accelerated approval for first-line treatment of advanced renal cell carcinoma and full approval for treatment of refractory gastrointestinal stromal tumors.

Bayer/Onyx’ Nexavar Approved For Kidney Cancer

FDA’s full approval of the oncologic indicates sorafenib for broad use by all patients with advanced renal cell carcinoma.

Topics

UsernamePublicRestriction

Register

SC081785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel